The salary figures of medical representatives are announced, and they are still rising!
The average salary of employees of foreign pharmaceutical companies is the highest, reaching 120,072 yuan, while that of private pharmaceutical companies is the lowest, which is only 76,004 yuan; it is worth noting that the average annual salary of sales positions is 129,298 yuan. In the entire pharmaceutical industry, the salary level of medical representatives is still Stay in the forefront, and maintain a certain increase.
Recently, according to a report by Securities Daily, among the 288 companies with year-on-year data in the pharmaceutical industry in 2018, 199 executives' compensation expenses increased, of which 126 companies' executives' compensation increased by more than 50%, and 14 companies' chairman compensation increased. The annual salary of the chairman of 35 companies was the same as that of 2017.
Among them, there are 4 chairmen whose salary exceeds 10 million yuan. They are Li Ge from WuXi AppTec, Li Xiting from Mindray Medical, Chen Qiyu from Fosun Pharma and Cui Jinhai from Ogilvy Medical. Their annual salaries are 17.646 million and 17.323 million respectively. million, 14.2504 million and 12.6959 million yuan. The lowest is Wang Minghui of Yunnan Baiyao, whose annual salary is only 27,600 yuan.
As far as general managers are concerned, the salaries of general managers of 105 listed companies exceed one million. WuXi AppTec, Mindray Medical and Fosun Pharma have an absolute advantage and the fourth place to widen the gap. The salaries of their general managers are 17.646 million and 16.6391 million respectively. million and 8.1382 million.
A few days ago, the editor published the per capita salary of employees of 23 pharmaceutical companies.
Minenet
A reader said in the backstage of Cyberblue: Most people's salaries are "averaged" - the high salary of the senior management team and the high salary of the salesmen with high commissions prove that the salary of the vast majority of people in the company is averaged .
What's more, the nominal salary is high, the hand salary is low, and deductions such as five insurances and one housing fund, personal income tax, disability insurance, labor union funds, various surcharges, and the company's human resources costs.
For example, a reader revealed that the total salary of twelve executives of a certain group is 24 million, and the total salary of more than 2,000 employees is 27 million, which is of little significance on average.
Therefore, we need more informative salary analysis.
The management consulting firm Jones Day and Park Xin obtained the pharmaceutical industry salary survey data report based on the salary level, salary increase, salary structure, turnover rate and other data of the pharmaceutical company industry.
The report shows that among the average salary and salary increases of the enterprise series in 2018, the average salary and salary increase of R&D employees are the highest, at 143,611 yuan and 13.4%, respectively, followed by the average salary of sales and marketing employees, which are 129,298 yuan and 103,722 yuan. Yuan, an increase of 7.5% and 8%.
This means that compared with other positions, the salary level of medical representatives is at the forefront, and it still maintains a certain increase.
From the perspective of industry segmentation type, the average salary and increase of pharmaceutical research and development are the highest, the average salary of chemical raw materials and preparations is the lowest, only 80,837 yuan, and the average salary of pharmaceutical business & retail is in the middle, 95,924 yuan.
In addition, the report also announces the level salary of each subdivision. The level salary distribution of director, supervisor, commissioner and other positions is listed, and the basic trend is also consistent with the average salary above.
From the perspective of the nature of the company, the average salary of employees of foreign pharmaceutical companies is the highest, reaching 120,072 yuan, while that of private pharmaceutical companies is the lowest, which is only 76,004 yuan.
All along, the treatment of foreign companies is better. Taking the sales position as an example, the data shows that the upper limit of Pfizer’s Pfizer is 11k, the upper limit of high-generation is 18k, and the subsidy is 1500 + 15% of the salary, and the salary is 12; Novartis’ Pfizer’s Pfizer is 6k-8k, 9k-12k, and the subsidy is 1800, 12 Salary; AbbVie's Pudai 6k+, Gaodai 8k+, supervisor 13k, regional 15k, subsidy 2k, 13 salary.
The average salary will also have a certain impact on the turnover rate. After analyzing the voluntary turnover rate of enterprises of different natures, the report found that the employees of private enterprises had the highest voluntary turnover rate, reaching 17.8%, followed by joint ventures, which was 14.2%. The lowest is for state-owned enterprises, and the voluntary turnover rate is only 6.5%.
From the perspective of positions, the overall turnover rate of sales positions is relatively high. Therefore, the overall turnover rate of pharmaceutical representatives of private pharmaceutical companies is relatively high.
Previously, medical crab data showed that the recruitment of medical representatives reached a new low: the market posting of medical representative/promotion/sales positions showed a continuous downward trend of fluctuation. From the overall job posting trend, the market demand for medical promotion posts was sharp after 2017. decline, and by the end of 2018, the trough of job demand was reached.
However, from the above salary report, it can be seen that the salary increase of sales positions in pharmaceutical companies still maintains an upward trend; in the entire pharmaceutical industry, the salary level of medical representatives still remains at the forefront.
It can be seen that the profession of medical representative still has vitality, but needs transformation and survival of the fittest.
We all know that the professional definition of a medical representative is "a professional who is engaged in drug information transmission, communication and feedback on behalf of a pharmaceutical manufacturer", but for a long time in the past, medical representative once became a "rebate" and "gold sales" the pronoun.
There have been opinions in the industry: Now the relevant departments have higher and higher requirements for compliance, the reduction of market fees has led to a reduction in rebates, and the pharmaceutical channels are constantly sinking. marketing model.
In this context, as long as medical representatives continue to accumulate professional skills and evolve themselves, meet the functional requirements of the post, and create value in the post, they can adapt to the needs of the constantly developing market for talents.